fda compounding semaglutide update restricts non-approved compounded GLP-1 weight loss products FDA Warns Against Using Compounded

Remember about strength-training activities that build muscle[7], such as lifting weights, using resistance bands, or your own body weight (push-ups or walking steps)

[1] [2] This reduces the risk of hypoglycaemia compared to some other diabetes medications

Talking to Your GP or Specialist About Weight Management Options Your GP is the appropriate first contact for weight management, able to assess eligibility for NICE-approved treatments and refer to specialist services

It works by mimicking GLP-1, which is a digestive hormone in the GI tract

NICE guidance (TA875) supports the use of semaglutide 2.4 mg (Wegovy) for adults with a BMI of 35 kg/m or above alongside at least one weight-related condition, within a specialist weight management service (with lower BMI thresholds applicable for certain ethnic groups and other commissioning criteria)

Legal Disclaimer This product is intended for laboratory research purposes only and is not approved for human or veterinary use